Parkinson's Disease Therapeutics
About This Book
Parkinson's Disease is the second most common neurodegenerative disorder in the elderly. Vital pathological events include a decline in nigrostriatal neurons and deterioration of the neurotransmitter dopamine. Since amyloid fibrils are the key end products of several proteins implicated in neurodegenerative diseases, multiple studies emphasize their diagnosis as the mainstay of current research. Despite remarkable progress in various PD therapeutics such as microRNAs and brain drug delivery systems, a few limitations impede their success. In addition, nanotechnological therapeutics avenues employed to date for brain diseases have not been as effective strategies as they are for other diseases. This book will shed light on the pros and cons of recently developed novel therapeutics. Very few books have highlighted the protective efficacy of natural products, antioxidants, and biomaterial design for other diseases. However, the efficacy of nanotechnology in overcoming the bioavailability issues associated with drugs, natural products and antioxidants, and their use in Parkinson's Disease therapy has not yet been summarized in the form of a book. Numerous unresolved major drawbacks of the existing therapeutic strategies and Nanotechnology in Parkinson's Disease treatment will be highlighted and possible future perspectives to overcome current challenges will be emphasized. Emphasizes novel therapeutics for Parkinson's disease including nanotechnology, natural products, and antioxidants Discusses the pros and cons of multiple recently developed therapy options for Parkinson's Focuses on the efficacy of nanotechnology in overcoming the blood-brain barrier and biomaterial design
